Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Lactobacillus johnsonii & Crohn’s disease (CD)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Randomized clinical trials (RCTs)

XXX - GETAID - Lactobacillus johnsonii LA1 & Crohn’s disease (CD)
Lactobacillus johnsonii LA1 was well tolerated, it did not significantly reduce recurrence to a clinically meaningful degree compared to a placebo.
Marteau et al. 2006 Gut. 55(6): 842–847

XXX - Lactobacillus johnsonii LA1 & Crohn’s disease (CD)
The oral administration of Lactobacillus johnsonii LA1 did not succeed in preventing the early endoscopic recurrence of Crohn’s disease
Van Gossum et al. 2007 Inflamm Bowel Dis. 13(2): 135–142

see also:
[Crohn's disease (CD) & Drugs/Treatments](brain://cKZKw_zWrk6Qbas9YQOmOw/CrohnsDiseaseCdDrugsTr…

References (Sources)

Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial
Marteau et al. 2006 Gut. 55(6): 842–847
Multicenter randomized controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after ileo-caecal resection
Van Gossum et al. 2007 Inflamm Bowel Dis. 13(2): 135–142

AI Chat

7/2/2026

Chat with our artificial intelligence:

Start chat!